Copyright Reports & Markets. All rights reserved.

Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Prevention
    • 1.4.3 Physiotherapy
    • 1.4.4 Immunity Therapy
  • 1.5 Market by Application
    • 1.5.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospitals
    • 1.5.3 Ambulatory Surgical Center
    • 1.5.4 Diagnostic Centers
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Perspective (2015-2026)
  • 2.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Growth Trends by Regions
    • 2.2.1 Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Share by Regions (2015-2020)
    • 2.2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Ventilator Associated Pneumonia (VAP) Therapeutics Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Ventilator Associated Pneumonia (VAP) Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Market Size
    • 3.1.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue (2015-2020)
    • 3.1.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio
    • 3.2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2019
  • 3.3 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players Head office and Area Served
  • 3.4 Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
  • 3.5 Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Type (2015-2020)
  • 4.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)
  • 5.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
  • 6.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in North America (2019-2020)
  • 6.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
  • 6.4 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
  • 7.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in Europe (2019-2020)
  • 7.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
  • 7.4 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

8 China

  • 8.1 China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
  • 8.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in China (2019-2020)
  • 8.3 China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
  • 8.4 China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
  • 9.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in Japan (2019-2020)
  • 9.3 Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
  • 9.4 Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
  • 10.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

11 India

  • 11.1 India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
  • 11.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in India (2019-2020)
  • 11.3 India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
  • 11.4 India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
  • 12.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
  • 12.4 Central & South America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Achaogen Inc
    • 13.1.1 Achaogen Inc Company Details
    • 13.1.2 Achaogen Inc Business Overview
    • 13.1.3 Achaogen Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 13.1.4 Achaogen Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020))
    • 13.1.5 Achaogen Inc Recent Development
  • 13.2 Adenium Biotech ApS
    • 13.2.1 Adenium Biotech ApS Company Details
    • 13.2.2 Adenium Biotech ApS Business Overview
    • 13.2.3 Adenium Biotech ApS Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 13.2.4 Adenium Biotech ApS Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 13.2.5 Adenium Biotech ApS Recent Development
  • 13.3 Aridis Pharmaceuticals LLC
    • 13.3.1 Aridis Pharmaceuticals LLC Company Details
    • 13.3.2 Aridis Pharmaceuticals LLC Business Overview
    • 13.3.3 Aridis Pharmaceuticals LLC Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 13.3.4 Aridis Pharmaceuticals LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 13.3.5 Aridis Pharmaceuticals LLC Recent Development
  • 13.4 AstraZeneca Plc
    • 13.4.1 AstraZeneca Plc Company Details
    • 13.4.2 AstraZeneca Plc Business Overview
    • 13.4.3 AstraZeneca Plc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 13.4.4 AstraZeneca Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 13.4.5 AstraZeneca Plc Recent Development
  • 13.5 Bayer AG
    • 13.5.1 Bayer AG Company Details
    • 13.5.2 Bayer AG Business Overview
    • 13.5.3 Bayer AG Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 13.5.4 Bayer AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 13.5.5 Bayer AG Recent Development
  • 13.6 Cardeas Pharma Corp
    • 13.6.1 Cardeas Pharma Corp Company Details
    • 13.6.2 Cardeas Pharma Corp Business Overview
    • 13.6.3 Cardeas Pharma Corp Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 13.6.4 Cardeas Pharma Corp Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 13.6.5 Cardeas Pharma Corp Recent Development
  • 13.7 Destiny Pharma Ltd
    • 13.7.1 Destiny Pharma Ltd Company Details
    • 13.7.2 Destiny Pharma Ltd Business Overview
    • 13.7.3 Destiny Pharma Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 13.7.4 Destiny Pharma Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 13.7.5 Destiny Pharma Ltd Recent Development
  • 13.8 Dong-A Socio Holdings Co Ltd
    • 13.8.1 Dong-A Socio Holdings Co Ltd Company Details
    • 13.8.2 Dong-A Socio Holdings Co Ltd Business Overview
    • 13.8.3 Dong-A Socio Holdings Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 13.8.4 Dong-A Socio Holdings Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 13.8.5 Dong-A Socio Holdings Co Ltd Recent Development
  • 13.9 Lakewood-Amedex Inc
    • 13.9.1 Lakewood-Amedex Inc Company Details
    • 13.9.2 Lakewood-Amedex Inc Business Overview
    • 13.9.3 Lakewood-Amedex Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 13.9.4 Lakewood-Amedex Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 13.9.5 Lakewood-Amedex Inc Recent Development
  • 13.10 MedImmune LLC
    • 13.10.1 MedImmune LLC Company Details
    • 13.10.2 MedImmune LLC Business Overview
    • 13.10.3 MedImmune LLC Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 13.10.4 MedImmune LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 13.10.5 MedImmune LLC Recent Development
  • 13.11 Meiji Seika Pharma Co Ltd
    • 10.11.1 Meiji Seika Pharma Co Ltd Company Details
    • 10.11.2 Meiji Seika Pharma Co Ltd Business Overview
    • 10.11.3 Meiji Seika Pharma Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 10.11.4 Meiji Seika Pharma Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 10.11.5 Meiji Seika Pharma Co Ltd Recent Development
  • 13.12 Merck & Co Inc
    • 10.12.1 Merck & Co Inc Company Details
    • 10.12.2 Merck & Co Inc Business Overview
    • 10.12.3 Merck & Co Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 10.12.4 Merck & Co Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 10.12.5 Merck & Co Inc Recent Development
  • 13.13 Motif Bio Plc
    • 10.13.1 Motif Bio Plc Company Details
    • 10.13.2 Motif Bio Plc Business Overview
    • 10.13.3 Motif Bio Plc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 10.13.4 Motif Bio Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 10.13.5 Motif Bio Plc Recent Development
  • 13.14 Nabriva Therapeutics AG
    • 10.14.1 Nabriva Therapeutics AG Company Details
    • 10.14.2 Nabriva Therapeutics AG Business Overview
    • 10.14.3 Nabriva Therapeutics AG Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 10.14.4 Nabriva Therapeutics AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 10.14.5 Nabriva Therapeutics AG Recent Development
  • 13.15 Polyphor Ltd
    • 10.15.1 Polyphor Ltd Company Details
    • 10.15.2 Polyphor Ltd Business Overview
    • 10.15.3 Polyphor Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 10.15.4 Polyphor Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 10.15.5 Polyphor Ltd Recent Development
  • 13.16 Shionogi & Co Ltd
    • 10.16.1 Shionogi & Co Ltd Company Details
    • 10.16.2 Shionogi & Co Ltd Business Overview
    • 10.16.3 Shionogi & Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 10.16.4 Shionogi & Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 10.16.5 Shionogi & Co Ltd Recent Development
  • 13.17 Tetraphase Pharmaceuticals Inc
    • 10.17.1 Tetraphase Pharmaceuticals Inc Company Details
    • 10.17.2 Tetraphase Pharmaceuticals Inc Business Overview
    • 10.17.3 Tetraphase Pharmaceuticals Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 10.17.4 Tetraphase Pharmaceuticals Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 10.17.5 Tetraphase Pharmaceuticals Inc Recent Development
  • 13.18 The Medicines Company
    • 10.18.1 The Medicines Company Company Details
    • 10.18.2 The Medicines Company Business Overview
    • 10.18.3 The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 10.18.4 The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 10.18.5 The Medicines Company Recent Development
  • 13.19 Theravance Biopharma Inc
    • 10.19.1 Theravance Biopharma Inc Company Details
    • 10.19.2 Theravance Biopharma Inc Business Overview
    • 10.19.3 Theravance Biopharma Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 10.19.4 Theravance Biopharma Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 10.19.5 Theravance Biopharma Inc Recent Development
  • 13.20 Wockhardt Ltd
    • 10.20.1 Wockhardt Ltd Company Details
    • 10.20.2 Wockhardt Ltd Business Overview
    • 10.20.3 Wockhardt Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 10.20.4 Wockhardt Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 10.20.5 Wockhardt Ltd Recent Development
  • 13.21 Zavante Therapeutics Inc
    • 10.21.1 Zavante Therapeutics Inc Company Details
    • 10.21.2 Zavante Therapeutics Inc Business Overview
    • 10.21.3 Zavante Therapeutics Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
    • 10.21.4 Zavante Therapeutics Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
    • 10.21.5 Zavante Therapeutics Inc Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Ventilator Associated Pneumonia (VAP) Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Ventilator Associated Pneumonia (VAP) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    Achaogen Inc
    Adenium Biotech ApS
    Aridis Pharmaceuticals LLC
    AstraZeneca Plc
    Bayer AG
    Cardeas Pharma Corp
    Destiny Pharma Ltd
    Dong-A Socio Holdings Co Ltd
    Lakewood-Amedex Inc
    MedImmune LLC
    Meiji Seika Pharma Co Ltd
    Merck & Co Inc
    Motif Bio Plc
    Nabriva Therapeutics AG
    Polyphor Ltd
    Shionogi & Co Ltd
    Tetraphase Pharmaceuticals Inc
    The Medicines Company
    Theravance Biopharma Inc
    Wockhardt Ltd
    Zavante Therapeutics Inc

    Market segment by Type, the product can be split into
    Prevention
    Physiotherapy
    Immunity Therapy
    Market segment by Application, split into
    Hospitals
    Ambulatory Surgical Center
    Diagnostic Centers

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now